Brief: New Micro-Simulation Study In Cancer Medicine Finds Epi ProColon Provides Clinically Meaningful Reductions In Incidence, Mortality Of Colorectal Cancer
29/11/2019 14:20
Nov 29 (Reuters) - Epigenomics AG ECXn.DE :
* NEW MICRO-SIMULATION STUDY IN CANCER MEDICINE FINDS EPI
PROCOLON
PROVIDES CLINICALLY MEANINGFUL REDUCTIONS IN INCIDENCE,
MORTALITY OF COLORECTAL CANCER
Source text for Eikon: ID:nGNX3P38JS
Further company coverage: ECXn.DE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns